Arkolith/Insider Trading/ATRS/Form 4

Smith Karen L.

DirectorANTARES PHARMA, INC. (ATRS) · full profile →Form 4 · filed May 26, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
2 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 24, 2022Disposed to issuer(D)25K$5.60$143K0
May 24, 2022Disposed to issuer(D)54K$5.60$303K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 24, 2022Disposed to issuer(D)58K——0
May 24, 2022Disposed to issuer(D)47K——0
May 24, 2022Disposed to issuer(D)20K——0
May 24, 2022Disposed to issuer(D)49K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-22-019793) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML